trial

Efficacy and Safety Study of Iloperidone Virus Risperidone to Treat Schizophrenia

NCTId NCT01623713
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 260 (actual)
Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.
Primary completion 2013-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
260 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2012-06
Primary completion
2013-10
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
IloperidoneRisperidone

Sponsors

Jiangsu Hansoh Pharmaceutical Co., Ltd.Lead Sponsor

Sites

1 total
Beijing, China

Linked catalysts

1
Efficacy and Safety Study of Iloperidone Virus Risperidone to Treat Schizophreni — primary completion2013-10

Facts & assertions

4 sourced
Enrollment
260
Phase
PHASE2
Primary Completion Date
2013-10
Status
COMPLETED
relationships
The graph out of here
drug
Iloperidone
drug
Risperidone
drug
lead_sponsor
Jiangsu Hansoh Pharmaceutical Co., Ltd.
company
indication
Schizophrenia
indication
Schizophrenia
indication
Iloperidone
indication